NASDAQ:TRPX Therapix Biosciences (TRPX) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free TRPX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.09▼$0.1250-Day Range$0.10▼$0.3252-Week Range$0.25▼$4.69Volume95,212 shsAverage Volume1.59 million shsMarket Capitalization$351,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Therapix Biosciences alerts: Email Address Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Therapix BiosciencesRead More Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> TRPX Stock News HeadlinesDecember 12, 2023 | benzinga.comAnixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, PredictionsAugust 23, 2023 | investing.comSagimet Biosciences Inc (SGMT)April 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...August 1, 2023 | seekingalpha.comPBIO Pressure BioSciences, Inc.January 19, 2022 | thestreet.comCannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOsSee More Headlines Receive TRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Therapix Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/20/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TRPX CUSIPN/A CIK1611746 Webtherapixbio.com Phone972-3616-7055FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares3,510,000Free FloatN/AMarket Cap$351,000.00 OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ascher Shmulewitz (Age 63)Chairman & Interim CEO Dr. Adi Zuloff-Shani (Age 51)Chief Technology Officer Mr. Oz Adler CPA (Age 32)Chief Financial Officer Key CompetitorsAptevo TherapeuticsNASDAQ:APVOAmpio PharmaceuticalsNYSE:AMPEObsEvaNASDAQ:OBSVAthersysNASDAQ:ATHXAllarity TherapeuticsNASDAQ:ALLRView All Competitors TRPX Stock Analysis - Frequently Asked Questions How were Therapix Biosciences' earnings last quarter? Therapix Biosciences Ltd. (NASDAQ:TRPX) announced its quarterly earnings data on Monday, August, 20th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.24. What other stocks do shareholders of Therapix Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Therapix Biosciences investors own include Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO), Tilray (TLRY), Corbus Pharmaceuticals (CRBP) and VBI Vaccines (VBIV). This page (NASDAQ:TRPX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Therapix Biosciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.